Immunoassay Market

Immunoassay Market (Product: Analyzers and Consumables; and Technology: Chemiluminescence Immunoassay, Enzyme-linked Immunoassay, Enzyme-linked Immunofluorescent Assay, Radioimmunoassay, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Immunoassay Market Outlook 2031

  • The industry was valued at US$ 31.5 Bn in 2022
  • It is estimated to grow at a CAGR of 5.0% from 2023 to 2031 and reach US$ 48.7 Bn by the end of 2031

Analyst Viewpoint

Increase in prevalence of chronic diseases and growth in biopharmaceutical and biotechnology industries are propelling the immunoassay market progress. Immunoassays are gaining popularity in the treatment of cancer, diabetes, and other chronic diseases. Growth in geriatric population is also boosting demand for immunoassays.

Rise in concerns regarding food contamination and lack of hygiene is likely to offer lucrative immunoassay market opportunities to key players. Leading players in the industry are investing in innovative drug development techniques to expand their product portfolio. They are also developing compact and innovative analyzers for mid to high-workflow laboratories.

Immunoassay Market

Market Introduction

Immunoassays or immunologic assays detect the presence of a specific molecule in a sample using antibody-antigen binding reactions. Immunoassays play a crucial role in several bioanalytical methodologies such as food monitoring, biopharmaceutical analysis, environmental monitoring and security, immune system tests, and clinical diagnostics. Immunoassays are developed to provide quantitative, semiquantitative, or qualitative detection of analytes.

Immunoassay testing works by utilizing antibodies to detect small biological substances in the blood and other bodily fluids. One of the popular methods of antibody testing is lateral flow immunoassay. Lateral flow immunoassay is a membrane-based technique to detect specific analytes in complex samples. High sensitivity and specificity, simple and user-friendly operation, and low sample volume requirement are major advantages of lateral flow immunoassay.

Increase in Prevalence of Chronic Diseases Augmenting Immunoassay Market Value

Changes in eating habits, sedentary lifestyles, and physical inactivity are leading to a surge in the prevalence of chronic diseases among the population. Immunoassay techniques are used to diagnose various chronic diseases including cardiovascular diseases, cancer, diabetes, nephrological diseases, mellitus, autoimmune diseases, and infections.

Growth in prevalence of cancer is propelling the immunoassay industry growth. According to the World Health Organization, cancer is a leading cause of fatalities globally and accounted for around 10 million deaths in 2020. The most common types of cancer diagnosed are lung, rectum and prostate, and breast cancers.

Cancer diagnosis is done using immunoassay techniques by analyzing genes, proteins, and other substances called tumor markers or biomarkers. Immunoassay techniques for cancer biomarkers are adopted to ensure early detection and accuracy of diagnosis. Thus, rise in demand for immunoassays in cancer diagnosis is driving the market dynamics.

Growth in Biopharmaceutical and Biotechnology Industries Fostering Market Statistics

Immunoassay are utilized in gene and cell therapy and vaccine development. Immunoassays provide a powerful and versatile analytical toolset in biopharmaceutical analysis, allowing manufacturers and researchers to assess the potency, safety, and quality of biopharmaceutical drugs. Public healthcare organizations and governments in various countries are investing in drug development, which is bolstering the immunoassay market size.

Immunoassays are extensively used for food toxins such as mycotoxins, pesticide residues, identification of bacteria and viruses, process-induced toxins and drugs, and detection of allergens in food. Food testing activities are increasing in the food & beverage sector due to the implementation of stringent government regulations on food safety. Hence, increase in awareness about maintaining food hygiene is boosting the market development.

Regional Outlook

As per the latest market insights, North America accounted for the largest market share in 2022. Increase in prevalence of infectious and chronic diseases and growth in geriatric population are augmenting the market expansion. Moreover, rapid development in healthcare infrastructure and surge in investment in drug development technologies are likely to bolster the immunoassay market share in the next few years.

According to the Pharmaceutical Research and Manufacturers of America, companies in the biopharmaceutical industry invested around US$ 102.3 Bn in research for drug development in 2021. As per the latest immunoassay market forecast, increase in research and development of advanced therapies for the treatment of chronic and cardiovascular diseases is projected to fuel the market value in the near future.

Analysis of Key Players in Immunoassay Market

Leading companies are following innovative immunoassay market trends to launch new diagnostic products. They are forming strategic partnerships and mergers to enhance their production capacities and broaden their presence in global markets. Key players are adopting advanced methodologies for the diagnosis and treatment of infectious diseases to improve business performance. They are also offering immunoassay techniques for cancer biomarkers.

Some of the players in the industry are F. Hoffmann-La Roche Ltd., Danaher Corporation, Abbott Laboratories, Siemens Healthineers (Siemens AG), DiaSorin S.p.A., Sysmex Corporation, bioMerieux SA, Ortho Clinical Diagnostics, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, and Merck kGaA.

These companies are profiled in the immunoassay industry report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.

Key Developments

  • In May 2022, Abbott Laboratories, a leading multinational medical devices and healthcare company, launched HBsAg Next Qualitative Assay in India to enhance the early detection of the Hepatitis B virus.
  • In November 2022, Getein Biotech Inc., a manufacturer of medical rapid test products, launched the MAGICL 6000 CLIA analyzer at MEDICA 2022. MAGICL 6000 is a compact and innovative CLIA analyzer, with optimal choice for mid to high-workflow laboratories that require a one-step CLIA solution.

Immunoassay Market Snapshot

Attribute Detail
Market Size in 2022 US$ 31.5 Bn
Market Forecast (Value) in 2031 US$ 48.7 Bn
Growth Rate (CAGR) 5.0%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Tons US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Product
    • Analyzer
    • Consumables
  • Technology
    • Chemiluminescence Immunoassay (CLIA)
    • Enzyme-linked Immunoassay (ELISA)
    • Enzyme-linked Immunofluorescent Assay (ELFA)
    • Radioimmunoassay (RIA)
    • Others
  • Application
    • Infectious Disease
    • Endocrinology
    • Oncology
    • Cardiology
    • Orthopedics
    • Others
  • End-user
    • Hospitals & Diagnostic Laboratories
    • Blood Banks
    • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC countries
Companies Profiled
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Abbott Laboratories
  • Siemens Healthineers (Siemens AG)
  • DiaSorin S.p.A.
  • Sysmex Corporation
  • bioMerieux SA
  • Ortho Clinical Diagnostics
  • Thermo Fisher Scientific, Inc.
  • Becton, Dickinson and Company
  • Merck kGaA
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global immunoassay market in 2022?

It was valued at US$ 31.5 Bn in 2022

How is the immunoassay sector expected to grow by 2031?

It is projected to register a CAGR of 5.0% from 2023 to 2031

What are the key factors driving the demand for immunoassay?

Increase in prevalence of chronic diseases and growth in biopharmaceutical and biotechnology industries

Which was the most lucrative region for immunoassay business in 2022?

North America was the most lucrative region in 2022

Who are the prominent immunoassay manufacturers?

F. Hoffmann-La Roche Ltd., Danaher Corporation, Abbott Laboratories, Siemens Healthineers (Siemens AG), DiaSorin S.p.A., Sysmex Corporation, bioMerieux SA, Ortho Clinical Diagnostics, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, and Merck kGaA

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Immunoassay Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Immunoassay Market Analysis and Forecast, 2017-2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Product/Brand Analysis

    5.3. Key Mergers & Acquisitions

    5.4. COVID-19 Pandemic Impact on Industry

6. Global Immunoassay Market Analysis and Forecast, by Product

    6.1. Introduction and Definitions

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Product, 2017–2031

        6.3.1. Analyzers

        6.3.2. Consumables

    6.4. Market Attractiveness, by Product

7. Global Immunoassay Market Analysis and Forecast, by Technology

    7.1. Introduction and Definitions

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Technology, 2017–2031

        7.3.1. Chemiluminescence Immunoassay (CLIA)

        7.3.2. Enzyme-linked Immunoassay (ELISA)

        7.3.3. Enzyme-linked Immunofluorescent Assay (ELFA)

        7.3.4. Radioimmunoassay (RIA)

        7.3.5. Others

        7.3.6. 7.4 Market Attractiveness, by Technology

8. Global Immunoassay Market Analysis and Forecast, by Application

    8.1. Introduction and Definitions

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Application, 2017–2031

        8.3.1. Infectious Disease

        8.3.2. Endocrinology

        8.3.3. Oncology

        8.3.4. Cardiology

        8.3.5. Orthopedics

        8.3.6. Others

    8.4. Market Attractiveness, by Application

9. Global Immunoassay Market Analysis and Forecast, by End-user

    9.1. Introduction and Definitions

    9.2. Key Findings/Developments

    9.3. Market Value Forecast, by End-user, 2017–2031

        9.3.1. Hospitals & Diagnostic Laboratories

        9.3.2. Blood Banks

        9.3.3. Others

    9.4. Market Attractiveness, by End-user

10. Global Immunoassay Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region, 2017–2031

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness, by Region

11. North America Immunoassay Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Product, 2017–2031

        11.2.1. Analyzers

        11.2.2. Consumables

    11.3. Market Attractiveness, by Product

    11.4. Market Value Forecast, by Technology, 2017–2031

        11.4.1. Chemiluminescence Immunoassay (CLIA)

        11.4.2. Enzyme-linked Immunoassay (ELISA)

        11.4.3. Enzyme-linked Immunofluorescent Assay (ELFA)

        11.4.4. Radioimmunoassay (RIA)

        11.4.5. Others

    11.5. Market Attractiveness, by Technology

    11.6. Market Value Forecast, by Application, 2017–2031

        11.6.1. Infectious Disease

        11.6.2. Endocrinology

        11.6.3. Oncology

        11.6.4. Cardiology

        11.6.5. Orthopedics

        11.6.6. Others

    11.7. Market Attractiveness, by Application

    11.8. Market Value Forecast, by End-user, 2017–2031

        11.8.1. Hospitals & Diagnostic Laboratories

        11.8.2. Blood Banks

        11.8.3. Others

    11.9. Market Attractiveness, by End-user

    11.10. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.10.1. U.S.

        11.10.2. Canada

    11.11. Market Attractiveness Analysis

        11.11.1. By Product

        11.11.2. By Technology

        11.11.3. By Application

        11.11.4. By End-user

        11.11.5. By Country

12. Europe Immunoassay Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Product, 2017–2031

        12.2.1. Analyzers

        12.2.2. Consumables

    12.3. Market Attractiveness, by Product

    12.4. Market Value Forecast, by Technology, 2017–2031

        12.4.1. Chemiluminescence Immunoassay (CLIA)

        12.4.2. Enzyme-linked Immunoassay (ELISA)

        12.4.3. Enzyme-linked Immunofluorescent Assay (ELFA)

        12.4.4. Radioimmunoassay (RIA)

        12.4.5. Others

    12.5. Market Attractiveness, by Technology

    12.6. Market Value Forecast, by Application, 2017–2031

        12.6.1. Infectious Disease

        12.6.2. Endocrinology

        12.6.3. Oncology

        12.6.4. Cardiology

        12.6.5. Orthopedics

        12.6.6. Others

    12.7. Market Attractiveness, by Application

    12.8. Market Value Forecast, by End-user, 2017–2031

        12.8.1. Hospitals & Diagnostic Laboratories

        12.8.2. Blood Banks

        12.8.3. Others

    12.9. Market Attractiveness, by End-user

    12.10. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.10.1. Germany

        12.10.2. U.K.

        12.10.3. France

        12.10.4. Italy

        12.10.5. Spain

        12.10.6. Rest of Europe

    12.11. Market Attractiveness Analysis

        12.11.1. By Product

        12.11.2. By Technology

        12.11.3. By Application

        12.11.4. By End-user

        12.11.5. By Country/Sub-region

13. Asia Pacific Immunoassay Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Product, 2017–2031

        13.2.1. Analyzers

        13.2.2. Consumables

    13.3. Market Attractiveness, by Product

    13.4. Market Value Forecast, by Technology, 2017–2031

        13.4.1. Chemiluminescence Immunoassay (CLIA)

        13.4.2. Enzyme-linked Immunoassay (ELISA)

        13.4.3. Enzyme-linked Immunofluorescent Assay (ELFA)

        13.4.4. Radioimmunoassay (RIA)

        13.4.5. Others

    13.5. Market Attractiveness, by Technology

    13.6. Market Value Forecast, by Application, 2017–2031

        13.6.1. Infectious Disease

        13.6.2. Endocrinology

        13.6.3. Oncology

        13.6.4. Cardiology

        13.6.5. Orthopedics

        13.6.6. Others

    13.7. Market Attractiveness, by Application

    13.8. Market Value Forecast, by End-user, 2017–2031

        13.8.1. Hospitals & Diagnostic Laboratories

        13.8.2. Blood Banks

        13.8.3. Others

    13.9. Market Attractiveness, by End-user

    13.10. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.10.1. China

        13.10.2. Japan

        13.10.3. India

        13.10.4. Australia & New Zealand

        13.10.5. Rest of Asia Pacific

    13.11. Market Attractiveness Analysis

        13.11.1. By Product

        13.11.2. By Technology

        13.11.3. By Application

        13.11.4. By End-user

        13.11.5. By Country/Sub-region

14. Latin America Immunoassay Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Product, 2017–2031

        14.2.1. Analyzers

        14.2.2. Consumables

    14.3. Market Attractiveness, by Product

    14.4. Market Value Forecast, by Technology, 2017–2031

        14.4.1. Chemiluminescence Immunoassay (CLIA)

        14.4.2. Enzyme-linked Immunoassay (ELISA)

        14.4.3. Enzyme-linked Immunofluorescent Assay (ELFA)

        14.4.4. Radioimmunoassay (RIA)

        14.4.5. Others

    14.5. Market Attractiveness, by Technology

    14.6. Market Value Forecast, by Application, 2017–2031

        14.6.1. Infectious Disease

        14.6.2. Endocrinology

        14.6.3. Oncology

        14.6.4. Cardiology

        14.6.5. Orthopedics

        14.6.6. Others

    14.7. Market Attractiveness, by Application

    14.8. Market Value Forecast, by End-user, 2017–2031

        14.8.1. Hospitals & Diagnostic Laboratories

        14.8.2. Blood Banks

        14.8.3. Others

    14.9. Market Attractiveness, by End-user

    14.10. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.10.1. Brazil

        14.10.2. Mexico

        14.10.3. Rest of Latin America

    14.11. Market Attractiveness Analysis

        14.11.1. By Product

        14.11.2. By Technology

        14.11.3. By Application

        14.11.4. By End-user

        14.11.5. By Country/Sub-region

15. Middle East & Africa Immunoassay Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Product, 2017–2031

        15.2.1. Analyzers

        15.2.2. Consumables

    15.3. Market Attractiveness, by Product

    15.4. Market Value Forecast, by Technology, 2017–2031

        15.4.1. Chemiluminescence Immunoassay (CLIA)

        15.4.2. Enzyme-linked Immunoassay (ELISA)

        15.4.3. Enzyme-linked Immunofluorescent Assay (ELFA)

        15.4.4. Radioimmunoassay (RIA)

        15.4.5. Others

    15.5. Market Attractiveness, by Technology

    15.6. Market Value Forecast, by Application, 2017–2031

        15.6.1. Infectious Disease

        15.6.2. Endocrinology

        15.6.3. Oncology

        15.6.4. Cardiology

        15.6.5. Orthopedics

        15.6.6. Others

    15.7. Market Attractiveness, by Application

    15.8. Market Value Forecast, by End-user, 2017–2031

        15.8.1. Hospitals & Diagnostic Laboratories

        15.8.2. Blood Banks

        15.8.3. Others

    15.9. Market Attractiveness, by End-user

    15.10. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.10.1. GCC Countries

        15.10.2. South Africa

        15.10.3. Rest of Middle East & Africa

    15.11. Market Attractiveness Analysis

        15.11.1. By Product

        15.11.2. By Technology

        15.11.3. By Application

        15.11.4. By End-user

        15.11.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player – Competition Matrix (By Tier and Size of Companies)

    16.2. Market Share Analysis, by Company (2022)

    16.3. Company Profiles

        16.3.1. F. Hoffmann-La Roche Ltd.

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Product Portfolio

            16.3.1.3. Financial Overview

            16.3.1.4. SWOT Analysis

            16.3.1.5. Strategic Overview

        16.3.2. Danaher Corporation

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Product Portfolio

            16.3.2.3. Financial Overview

            16.3.2.4. SWOT Analysis

            16.3.2.5. Strategic Overview

        16.3.3. Abbott Laboratories

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Product Portfolio

            16.3.3.3. Financial Overview

            16.3.3.4. SWOT Analysis

            16.3.3.5. Strategic Overview

        16.3.4. Siemens Healthineers (Siemens AG)

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Product Portfolio

            16.3.4.3. Financial Overview

            16.3.4.4. SWOT Analysis

            16.3.4.5. Strategic Overview

        16.3.5. DiaSorin S.p.A.

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Product Portfolio

            16.3.5.3. Financial Overview

            16.3.5.4. SWOT Analysis

            16.3.5.5. Strategic Overview

        16.3.6. Sysmex Corporation

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Product Portfolio

            16.3.6.3. Financial Overview

            16.3.6.4. SWOT Analysis

            16.3.6.5. Strategic Overview

        16.3.7. bioMerieux SA

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Product Portfolio

            16.3.7.3. Financial Overview

            16.3.7.4. SWOT Analysis

            16.3.7.5. Strategic Overview

        16.3.8. Ortho Clinical Diagnostics

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Product Portfolio

            16.3.8.3. Financial Overview

            16.3.8.4. SWOT Analysis

            16.3.8.5. Strategic Overview

        16.3.9. Thermo Fisher Scientific, Inc.

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Product Portfolio

            16.3.9.3. Financial Overview

            16.3.9.4. SWOT Analysis

            16.3.9.5. Strategic Overview

        16.3.10. Becton, Dickinson and Company

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Product Portfolio

            16.3.10.3. Financial Overview

            16.3.10.4. SWOT Analysis

            16.3.10.5. Strategic Overview

        16.3.11. Merck kGaA

            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.11.2. Product Portfolio

            16.3.11.3. Financial Overview

            16.3.11.4. SWOT Analysis

            16.3.11.5. Strategic Overview

List of Tables

Table 01: Global Immunoassay Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 02: Global Immunoassay Market Size (US$ Mn) Forecast, by Technology, 2017–2031

Table 03: Global Immunoassay Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Global Immunoassay Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 05: Global Immunoassay Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Immunoassay Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Immunoassay Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 08: North America Immunoassay Market Size (US$ Mn) Forecast, by Technology, 2017–2031

Table 09: North America Immunoassay Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 10: North America Immunoassay Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 11: Europe Immunoassay Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Immunoassay Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 13: Europe Immunoassay Market Size (US$ Mn) Forecast, by Technology, 2017–2031

Table 14: Europe Immunoassay Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 15: Europe Immunoassay Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Immunoassay Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Immunoassay Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 18: Asia Pacific Immunoassay Market Size (US$ Mn) Forecast, by Technology, 2017–2031

Table 19: Asia Pacific Immunoassay Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 20: Asia Pacific Immunoassay Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Latin America Immunoassay Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Immunoassay Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 23: Latin America Immunoassay Market Size (US$ Mn) Forecast, by Technology, 2017–2031

Table 24: Latin America Immunoassay Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 25: Latin America Immunoassay Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 26: Middle East & Africa Immunoassay Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Middle East & Africa Immunoassay Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 28: Middle East & Africa Immunoassay Market Size (US$ Mn) Forecast, by Technology, 2017–2031

Table 29: Middle East & Africa Immunoassay Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 30: Middle East & Africa Immunoassay Market Size (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Immunoassay Market Size (US$ Mn), by Region, 2022 and 2031

Figure 02: Global Immunoassay Market Revenue (US$ Mn), by Product, 2022

Figure 03: Global Immunoassay Market Value Share, by Product, 2022

Figure 04: Global Immunoassay Market Revenue (US$ Mn), by Technology, 2022

Figure 05: Global Immunoassay Market Value Share, by Technology, 2022

Figure 06: Global Immunoassay Market Revenue (US$ Mn), by Application, 2022

Figure 07: Global Immunoassay Market Value Share, by Application, 2022

Figure 08: Global Immunoassay Market Revenue (US$ Mn), by End-user, 2022

Figure 09: Global Immunoassay Market Value Share, by End-user, 2022

Figure 10: Global Immunoassay Market Value Share, by Region, 2022

Figure 11: Global Immunoassay Market Value (US$ Mn) Forecast, 2017–2031

Figure 12: Global Immunoassay Market Value Share Analysis, by Product, 2022 and 2031

Figure 13: Global Immunoassay Market Attractiveness Analysis, by Product, 2023-2031

Figure 14: Global Immunoassay Market Value Share Analysis, by Technology, 2022 and 2031

Figure 15: Global Immunoassay Market Attractiveness Analysis, by Technology, 2023-2031

Figure 16: Global Immunoassay Market Value Share Analysis, by Application, 2022 and 2031

Figure 17: Global Immunoassay Market Attractiveness Analysis, by Application, 2023-2031

Figure 18: Global Immunoassay Market Revenue (US$ Mn), by End-user, 2022

Figure 19: Global Immunoassay Market Value Share, by End-user, 2022

Figure 20: Global Immunoassay Market Value Share Analysis, by Region, 2022 and 2031

Figure 21: Global Immunoassay Market Attractiveness Analysis, by Region, 2023-2031

Figure 22: North America Immunoassay Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 23: North America Immunoassay Market Attractiveness Analysis, by Country, 2023–2031

Figure 24: North America Immunoassay Market Value Share Analysis, by Country, 2022 and 2031

Figure 25: North America Immunoassay Market Value Share Analysis, by Product, 2022 and 2031

Figure 26: North America Immunoassay Market Value Share Analysis, by Technology, 2022 and 2031

Figure 27: North America Immunoassay Market Value Share Analysis, by Application, 2022 and 2031

Figure 28: North America Immunoassay Market Value Share Analysis, by End-user, 2022 and 2031

Figure 29: North America Immunoassay Market Attractiveness Analysis, by Product, 2023–2031

Figure 30: North America Immunoassay Market Attractiveness Analysis, by Technology, 2023–2031

Figure 31: North America Immunoassay Market Attractiveness Analysis, by Application, 2023–2031

Figure 32: North America Immunoassay Market Attractiveness Analysis, by End-user, 2023–2031

Figure 33: Europe Immunoassay Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 34: Europe Immunoassay Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 35: Europe Immunoassay Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 36: Europe Immunoassay Market Value Share Analysis, by Product, 2022 and 2031

Figure 37: Europe Immunoassay Market Value Share Analysis, by Technology, 2022 and 2031

Figure 38: Europe Immunoassay Market Value Share Analysis, by Application, 2022 and 2031

Figure 39: Europe Immunoassay Market Value Share Analysis, by End-user, 2022 and 2031

Figure 40: Europe Immunoassay Market Attractiveness Analysis, by Product, 2023–2031

Figure 41: Europe Immunoassay Market Attractiveness Analysis, by Technology, 2023–2031

Figure 42: Europe Immunoassay Market Attractiveness Analysis, by Application, 2023–2031

Figure 43: Europe Immunoassay Market Attractiveness Analysis, by End-user, 2023–2031

Figure 44: Asia Pacific Immunoassay Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 45: Asia Pacific Immunoassay Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 46: Asia Pacific Immunoassay Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 47: Asia Pacific Immunoassay Market Value Share Analysis, by Product, 2022 and 2031

Figure 48: Asia Pacific Immunoassay Market Value Share Analysis, by Technology, 2022 and 2031

Figure 49: Asia Pacific Immunoassay Market Value Share Analysis, by Application, 2022 and 2031

Figure 50: Asia Pacific Immunoassay Market Value Share Analysis, by End-user, 2022 and 2031

Figure 51: Asia Pacific Immunoassay Market Attractiveness Analysis, by Product, 2023–2031

Figure 52: Asia Pacific Immunoassay Market Attractiveness Analysis, by Technology, 2023–2031

Figure 53: Asia Pacific Immunoassay Market Attractiveness Analysis, by Application, 2023–2031

Figure 54: Asia Pacific Immunoassay Market Attractiveness Analysis, by End-user, 2022–2031

Figure 55: Latin America Immunoassay Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 56: Latin America Immunoassay Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 57: Latin America Immunoassay Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 58: Latin America Immunoassay Market Value Share Analysis, by Product, 2022 and 2031

Figure 59: Latin America Immunoassay Market Value Share Analysis, by Technology, 2022 and 2031

Figure 60: Latin America Immunoassay Market Value Share Analysis, by Application, 2022 and 2031

Figure 61: Latin America Immunoassay Market Value Share Analysis, by End-user, 2022 and 2031

Figure 62: Latin America Immunoassay Market Attractiveness Analysis, by Product, 2023–2031

Figure 63: Latin America Immunoassay Market Attractiveness Analysis, by Technology, 2023–2031

Figure 64: Latin America Immunoassay Market Attractiveness Analysis, by Application, 2023–2031

Figure 65: Latin America Immunoassay Market Attractiveness Analysis, by End-user, 2023–2031

Figure 66: Middle East & Africa Immunoassay Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 67: Middle East & Africa Immunoassay Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 68: Middle East & Africa Immunoassay Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 69: Middle East & Africa Immunoassay Market Value Share Analysis, by Product, 2022 and 2031

Figure 70: Middle East & Africa Immunoassay Market Value Share Analysis, by Technology, 2022 and 2031

Figure 71: Middle East & Africa Immunoassay Market Value Share Analysis, by Application, 2022 and 2031

Figure 72: Middle East & Africa Immunoassay Market Value Share Analysis, by End-user, 2022 and 2031

Figure 73: Middle East & Africa Immunoassay Market Attractiveness Analysis, by Product, 2023–2031

Figure 74: Middle East & Africa Immunoassay Market Attractiveness Analysis, by Technology, 2023–2031

Figure 75: Middle East & Africa Immunoassay Market Attractiveness Analysis, by Application, 2023–2031

Figure 76: Middle East & Africa Immunoassay Market Attractiveness Analysis, by End-user, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved